[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Matsakas EP, Lazaros GA, Panou FK, Karavidas AI, Papalimberi EP, Scotis ID, Zacharoulis AA: Primary pericardial fibrosarcoma presenting as "near" cardiac tamponade. Clin Cardiol; 2002 Feb;25(2):83-5
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pericardial fibrosarcoma presenting as "near" cardiac tamponade.
  • Diagnostic investigations, such as echocardiography and magnetic resonance imaging, provided evidence of a large mass within the pericardial sac, attached by a broad base to the parietal pericardium and lying along the right ventricular free wall.
  • A partial pericardiectomy was performed to relieve the patient's symptoms, and histologic examination of a biopsy specimen showed features of a malignant, spindle cell, mesenchymal neoplasm.
  • The patient underwent surgical treatment during which the tumor was found to infiltrate the anterior surface of the right ventricle.
  • Histologically, the tumor was identified as a high-grade fibrosarcoma, and additional chemotherapy was given.
  • [MeSH-major] Cardiac Tamponade / etiology. Fibrosarcoma / diagnosis. Heart Neoplasms / diagnosis. Pericardium
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11841156.001).
  • [ISSN] 0160-9289
  • [Journal-full-title] Clinical cardiology
  • [ISO-abbreviation] Clin Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Onan B, Onan IS, Polat B: Surgical resection of solitary metastasis of malignant melanoma to the right atrium. Tex Heart Inst J; 2010;37(5):598-601
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of solitary metastasis of malignant melanoma to the right atrium.
  • Malignant melanoma has a very high tendency to metastasize to the heart.
  • Although most cardiac metastases of melanomas are clinically silent, the lesions may present with life-threatening cardiac morbidities, including dysrhythmia, right ventricular outflow tract obstruction, myocardial dysfunction, pericardial effusion, or heart failure.
  • In selected patients who have a solitary intracardiac melanoma, surgical resection can provide relief from clinical symptoms and minimize potential cardiac sequelae of the tumor.
  • Because tumor embolization of cardiac melanoma has been reported, the presence of atrial metastatic melanoma can be another indication for surgery.Herein, we present the case of a 31-year-old man who had a right atrial metastatic melanoma of unknown primary origin.
  • He underwent surgical resection of the tumor before beginning a course of chemotherapy.

  • MedlinePlus Health Information. consumer health - Heart Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2000 Nov;75(3):203-7 [11088053.001]
  • [Cites] J Vasc Surg. 2002 Jul;36(1):191-3 [12096280.001]
  • [Cites] Semin Nucl Med. 2004 Oct;34(4):242-53 [15493002.001]
  • [Cites] Am J Cardiol. 1968 Apr;21(4):555-71 [5650736.001]
  • [Cites] J Vasc Surg. 1986 Mar;3(3):550-3 [3951038.001]
  • [Cites] Heart Lung. 2006 Sep-Oct;35(5):351-4 [16963367.001]
  • [Cites] Ann Thorac Surg. 1996 Apr;61(4):1255-7 [8607700.001]
  • [Cites] Mayo Clin Proc. 1996 Dec;71(12):1167-70 [8945488.001]
  • [Cites] Ann Thorac Surg. 1998 Mar;65(3):844-6 [9527233.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Mar;15(3):373-5 [10333039.001]
  • [Cites] Europace. 2006 Jul;8(7):545-8 [16798769.001]
  • [Cites] Cancer Metastasis Rev. 1987;6(4):559-93 [3327633.001]
  • (PMID = 20978580.001).
  • [ISSN] 1526-6702
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2953215
  • [Keywords] NOTNLM ; Endocardium/pathology / heart atria/surgery/ultrasonography / heart neoplasms/complications/diagnosis/pathology/secondary/surgery / image interpretation, computer-assisted/methods / melanoma/diagnosis/secondary/surgery / neoplasm metastasis / neoplasms, unknown primary / prognosis / treatment outcome
  •  go-up   go-down


3. Hassan M, Seoud DE: Multimodality treatments in locally advanced stage thymomas. Hematol Oncol Stem Cell Ther; 2009;2(2):340-4
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatments in locally advanced stage thymomas.
  • BACKGROUND AND OBJECTIVES: Complete surgical resection is the main goal in the treatment of thymoma, but is not always achievable in stage III and IVA thymoma because of local invasion of the neighboring organs or the presence of diffuse pleural or pericardial implants.
  • We reviewed our experience in multimodality treatment of advanced stage (III and IVA) thymic tumors to evaluate the effectiveness and safety in patients with locally advanced unresectable thymoma.
  • PATIENTS AND METHODS: We studied patients with newly diagnosed, histologically proven, unresectable malignant thymoma who underwent a multimodality treatment regimen that consisted of neoadjuvant chemotherapy (three courses of cisplatin and etoposide), followed by surgical resection, postoperative radiation therapy, and consolidation chemotherapy (three courses of cisplatin and etposide).
  • Disease responded to neoadjuvant chemotherapy completely in 1 patient (11%) and partially in 6 patients (66%) with an overall response of 77%.
  • All patients received radiation therapy and consolidation chemotherapy.
  • The major side effect from neoadjuvant and consolidation chemotherapy was myelosuppression.
  • CONCLUSION: The multimodality treatment of stage III and IVA thymic tumors by integration of surgery, radio- therapy, and chemotherapy, contributed to a good long-term outcome.
  • The neoadjuvant chemotherapy improves the resectability rate and the survival of locally advanced stages of the disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Radiotherapy Dosage. Thymectomy. Thymoma / therapy. Thymus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118057.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Catalano A, Graciotti L, Rinaldi L, Raffaelli G, Rodilossi S, Betta P, Gianni W, Amoroso S, Procopio A: Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer; 2004 Apr 10;109(3):322-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention.
  • Malignant mesothelioma (MM) remains the most lethal pleural, peritoneal and pericardial cancer.
  • Unlike primary normal mesothelial cells, the selective cyclooxygenase (COX)-2 inhibitor celecoxib reduced the in vitro proliferation of several MM cells derived from previously untreated MM patients.
  • Celecoxib, in a dose- and time-dependent manner, induced MM cell apoptosis, which involved decreased Akt phosphorylation, loss of Bcl-2 and Survivin protein expression and caspase-3 activation.
  • These data demonstrate that celecoxib may have antitumor properties in MM and provide a rationale for the therapeutic use of celecoxib in combination with a selective VEGF inhibitor.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Mesothelioma / drug therapy. Protein-Serine-Threonine Kinases. Proto-Oncogene Proteins / antagonists & inhibitors. Sulfonamides / therapeutic use
  • [MeSH-minor] Animals. Apoptosis. Caspase 3. Caspases / metabolism. Celecoxib. Chemoprevention. Cyclooxygenase Inhibitors / pharmacology. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt. Proto-Oncogene Proteins c-bcl-2 / metabolism. Pyrazoles. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 14961568.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase Inhibitors; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazoles; 0 / Sulfonamides; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


5. Zhang BL, Xu RL, Zheng X, Qin YW: A case with cardiac tamponade as the first sign of primary gastric signet-ring cell carcinoma treated with combination therapy. Med Sci Monit; 2010 Apr;16(4):CS41-44
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case with cardiac tamponade as the first sign of primary gastric signet-ring cell carcinoma treated with combination therapy.
  • BACKGROUND: This report presents a rare patient with cardiac tamponade as the first manifestation of primary gastric signet-ring cell carcinoma.
  • CASE REPORT: A 56-year-old woman with emergent dyspnea, anterior chest oppression, and hypotension was diagnosed as having cardiac tamponade due to massive pericardial effusion.
  • The endoscopic examination of the stomach disclosed gastric cancer in the posterior wall of the antrum and the biopsy showed signet-ring cell carcinoma.
  • The gastric cancer was complicated by malignant pericardial effusion and pleural effusion as well as metastasis to the peripheral lymph nodes and bones.
  • The patient was treated with percutaneous pericardiocentesis followed by systemic chemotherapy (oxaliplatin and sequential 5-fluorouracil plus leucovorin).
  • The pericardial effusion gradually disappeared and there was no cardiac tamponade occurrence.
  • CONCLUSIONS: Cardiac tamponade may originate from a primary gastric signet-ring cell carcinoma.
  • Pericardiocentesis followed by systemic chemotherapy may be effective in controlling such advanced gastric signet-ring cell carcinoma.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / drug therapy. Cardiac Tamponade / complications. Cardiac Tamponade / diagnosis. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20357721.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Shitara K, Munakata M, Ishiguro A, Kudo T, Okada R, Tomioka R, Mitobe S, Yokoyama S, Sakata Y: [Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1497-1500
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma].
  • BACKGROUND: Colonic perforation due to colitis is a known and reported side effect of chemotherapy.
  • CASE REPORT: A 53-year-old woman was treated with combination chemotherapy of irinotecan plus cisplatin for a recurrent ovarian clear cell adenocarcinoma.
  • After two cycles of treatment, she developed a colonic perforation.
  • Emergency laparotomy was not performed because of poor performance status with multiple lung metastases, pleural effusion and pericardial effusion.
  • Oral intake could be restarted for a while, but she died from tumor progression one and a half months after the diagnosis of perforation.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cecal Diseases / etiology. Intestinal Perforation / etiology. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Colonoscopy. Drainage. Drug Administration Schedule. Fatal Outcome. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Pleural Effusion, Malignant / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033246.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Hasegawa S, Ito H, Kojima Y, Nakayama H, Wada N, Inui K, Imoto K, Rino Y, Takanashi Y: [A case of thymic cancer with pericardial tamponade as initial manifestation]. Gan To Kagaku Ryoho; 2006 Jan;33(1):79-82
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of thymic cancer with pericardial tamponade as initial manifestation].
  • We report a case of thymic cancer with pericardial tamponade in a 70-year-old woman.
  • CT scan showed a mediastinal mass and massive pericardial effusion.
  • The effusion was serous fluid, not bloody, and no malignant cells were found.
  • The patient underwent a tumor resection, and the final pathological diagnosis was squamous cell carcinoma of the thymus.
  • In a review of 14 cases of thymic tumor with pericardial tamponade as initial manifestations in the Japanese literature,there were only three cases of thymic cancer.
  • The prognosis was reported to be extremely poor.Some reports showed the effectiveness of chemotherapy and irradiation therapy.
  • We should keep looking for the best treatment for this disease.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Cardiac Tamponade / etiology. Thymus Neoplasms / complications
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Combined Modality Therapy. Female. Humans. Liver Neoplasms / secondary. Pericardial Effusion / etiology

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410702.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Maruyama R, Sakai M, Nakamura T, Suemitsu R, Okamoto T, Wataya H, Nishiyama K, Kamei T, Ichinose Y: Triplet chemotherapy for malignant pericardial mesothelioma: a case report. Jpn J Clin Oncol; 2006 Apr;36(4):245-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triplet chemotherapy for malignant pericardial mesothelioma: a case report.
  • Malignant pericardial mesothelioma (MPM) is a relatively rare neoplasm in Japan, and no standard treatment regimens have been established for this disease.
  • A 47-year-old woman with MPM presenting with cardiac tamponade was treated using four cycles of chemotherapy consisting of cisplatin (CDDP) 40 mg/m2, gemcitabine (GEM) 800 mg/m2 and vinorelbine (VNR) 20 mg/m2 on days 1 and 8 every 4 weeks after pericardial drainage alone.
  • The diagnosis of MPM was confirmed by an immunohistochemical procedure using either positive or negative markers of malignant mesothelioma in addition to conventional cytological examinations using pericardial effusion.
  • The patient has returned to her usual activities and has remained well for 24 months after the last chemotherapy without any evidence of disease progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Neoplasms / drug therapy. Mesothelioma / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drainage. Drug Administration Schedule. Female. Humans. Middle Aged. Neutropenia / chemically induced. Pericardial Effusion / pathology. Remission Induction. Survivors. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533802.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


9. Einama T, Sato K, Tsuda H, Mochizuki H: Successful treatment of malignant pericardial effusion, using weekly paclitaxel, in a patient with breast cancer. Int J Clin Oncol; 2006 Oct;11(5):412-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of malignant pericardial effusion, using weekly paclitaxel, in a patient with breast cancer.
  • We report a case of metastatic breast cancer with pericardial effusion that was successfully treated with weekly paclitaxel.
  • A diagnosis of cardiac tamponade due to breast cancer relapse was made, and the patient was treated with weekly paclitaxel (80 mg/m2) and insertion of a drainage catheter.
  • This treatment was effective in preventing reaccumulation of the pericardial effusion until her death.
  • The concentration of paclitaxel in the cardiac effusion was 45 ng/ml at 3 h, 15 ng/ml at 12 h, and less than 10 ng/ml at 24 h after paclitaxel infusion, indicating good transportation of the drug from the blood to the pericardial effusion.
  • These findings suggest that weekly intravenous infusion of paclitaxel could be effective for the treatment of patients with malignant pericardial effusion.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Paclitaxel / therapeutic use. Pericardial Effusion / therapy
  • [MeSH-minor] Cardiac Tamponade / etiology. Cardiac Tamponade / therapy. Drainage. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Staging. Pericardiocentesis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 2003 Aug;33(8):371-6 [14523055.001]
  • [Cites] JAMA. 1994 Jul 6;272(1):59-64 [8007081.001]
  • [Cites] JAMA. 1982 Feb 26;247(8):1143-8 [7057604.001]
  • [Cites] Semin Oncol. 1978 Jun;5(2):181-92 [353988.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Mar;31(3):449-51 [15045960.001]
  • [Cites] Clin Cancer Res. 1995 Jun;1(6):599-606 [9816021.001]
  • [Cites] J Surg Oncol. 1984 Sep;27(1):42-4 [6482451.001]
  • [Cites] Am J Med. 1978 Nov;65(5):808-14 [707539.001]
  • [Cites] Arch Intern Med. 1975 Jul;135(7):976-7 [1156057.001]
  • [Cites] Heart. 1996 Jan;75(1):67-71 [8624876.001]
  • [Cites] Am J Med. 1993 Aug;95(2):209-13 [8356985.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1697-1704 [7370925.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2061-8 [15169793.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Dec 27;44 Suppl:S15-30 [12505596.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):76-80 [1702345.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):14-8 [8630921.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1377-87 [8620412.001]
  • [Cites] Am Heart J. 1986 Jun;111(6):1138-42 [3716989.001]
  • [Cites] Cancer Treat Rep. 1987 Dec;71(12):1179-84 [2891442.001]
  • [Cites] Oncologist. 1998;3(6):373-389 [10388129.001]
  • (PMID = 17058141.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Khalil MY, Mapa M, Shin HJ, Shin DM: Advances in the management of malignant mesothelioma. Curr Oncol Rep; 2003 Jul;5(4):334-41
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the management of malignant mesothelioma.
  • Malignant mesotheliomas are very aggressive tumors that originate from mesothelial cells, which form the serosal lining of the pleura, pericardial, and peritoneal cavities.
  • Finding effective chemotherapeutic treatment for malignant mesothelioma is a challenge.
  • There is no standard treatment because this tumor is relatively resistant to therapy.
  • A resurgence of interest has been expressed in novel therapies and conventional treatments used in different ways.
  • Several treatment modalities have been studied, including chemotherapy, radiotherapy, surgery, and immunotherapy.
  • Chemotherapy can be administered systemically or directly into the pleura.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Mesothelioma / pathology. Mesothelioma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Genetic Therapy / methods. Humans. Immunotherapy / methods. Lung Neoplasms / mortality. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Male. Neoplasm Staging. Pleural Neoplasms / mortality. Pleural Neoplasms / pathology. Pleural Neoplasms / therapy. Prognosis. Radiotherapy / methods. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Thoracic Surgical Procedures / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1995 Sep;108(3):754-8 [7656629.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):19-25 [6174494.001]
  • [Cites] Carcinogenesis. 2002 Jun;23(6):1017-24 [12082024.001]
  • [Cites] Hum Gene Ther. 1998 May 1;9(7):1083-92 [9607419.001]
  • [Cites] Oncogene. 1995 Aug 3;11(3):511-5 [7630635.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2053-63 [10815932.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 20;91(2):169-75 [9923859.001]
  • [Cites] Int J Oncol. 2001 May;18(5):1093-8 [11295061.001]
  • [Cites] Am J Clin Pathol. 1998 Sep;110(3):397-404 [9728617.001]
  • [Cites] Hum Gene Ther. 1999 Feb 10;10(3):463-75 [10048398.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):62-9 [11836670.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1436-42 [8021735.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2293-300 [10829050.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):167-72 [10395286.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 15;84(2):116-9 [8536224.001]
  • [Cites] J Pathol. 2001 Apr;193(4):468-75 [11276005.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1985-91 [10570422.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(12):1514-21 [10930799.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):82-96 [11836673.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):99-106 [9892193.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3912-7 [11099320.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2577-82 [10375105.001]
  • [Cites] Chest. 1998 Jan;113(1 Suppl):66S-73S [9438693.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Feb;115(2):310-7; discussion 317-8 [9475525.001]
  • [Cites] Lung Cancer. 2001 Feb-Mar;31(2-3):311-7 [11165412.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):361-6 [9352953.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):25-30 [10458214.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):373-9 [9815694.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1156-63 [8201377.001]
  • [Cites] Biochem Pharmacol. 2001 Jul 1;62(1):13-9 [11377392.001]
  • [Cites] Mol Carcinog. 1999 Oct;26(2):93-9 [10506753.001]
  • [Cites] Ann Thorac Surg. 1997 Feb;63(2):334-8 [9033296.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):147-53 [3335886.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 20;87(24):1870-5 [7494231.001]
  • [Cites] Cancer Genet Cytogenet. 1988 Jul 15;33(2):251-74 [3164248.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):313-9 [1988578.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Feb;26(2):189-93 [11804869.001]
  • [Cites] Clin Lung Cancer. 1999 Aug;1(1):73-5 [14725755.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3009-16 [10506594.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):143-7 [11319288.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3533-44 [12177114.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Oct;29(2):173-9 [10959097.001]
  • [Cites] Lung Cancer. 2006 May;52(2):199-206 [16542747.001]
  • [Cites] Cancer. 2003 Aug 25;99(4):233-9 [12925985.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):121-9 [11936818.001]
  • [Cites] Am Rev Respir Dis. 1991 Feb;143(2):408-22 [1990961.001]
  • [Cites] Cancer Genet Cytogenet. 1990 Jul 1;47(1):1-28 [2357680.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 [10991971.001]
  • [Cites] J Microencapsul. 1994 Jan-Feb;11(1):41-54 [8138874.001]
  • [Cites] J Pathol. 2002 Jun;197(2):218-23 [12015746.001]
  • [Cites] Br J Cancer. 1992 Jun;65(6):956-60 [1616870.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Apr;117(4):759-65 [10096972.001]
  • (PMID = 12781077.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


11. Veronesi G, Spaggiari L, Mazzarol G, De Pas M, Leo F, Solli P, Pastorino U: Huge malignant localized fibrous tumor of the pleura. J Cardiovasc Surg (Torino); 2000 Oct;41(5):781-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge malignant localized fibrous tumor of the pleura.
  • Localized fibrous tumor is an unfrequent mesenchymal neoplasm.
  • The malignant variant of the pleura is exceptional and differential diagnosis with the more frequent benign type or with other neoplasms such as soft tissue sarcoma and mesothelioma is rarely possible in a preoperative setting.
  • The best treatment of this disease is radical surgical resection.
  • No definitive data exist about the role of chemotherapy.
  • We report a case of a giant right intrathoracic mass whose preoperative diagnosis, from an open biopsy, was consistent with sarcoma and, in a second review, with fibrous tumor of the pleura without any indication about malignancy.
  • A right pleuropneumonectomy and pericardial resection was performed through a right hemiclam-shell approach.
  • In consideration of the apparent local radicality we did not perform any adjuvant treatment.
  • Six months after the operation a wide local recurrence was evident and a systemic treatment with Ifosfamide and Adriamicina is still in progress.
  • Preoperative diagnosis of malignancy has an important role as a therapeutic strategy in management of fibrous tumours of the pleura.
  • When there is suspicion of a malignant form neoadjuvant chemotherapy can represent a further tool to control poorly differentiated and large tumors, and a wide surgical resection of the lesion must be performed.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Doxorubicin / therapeutic use. Humans. Ifosfamide / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Pneumonectomy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11149649.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


12. Sakai T, Kimura D, Tsushima T, Hatanaka R, Yamada Y, Fukuda I: [Assessment of surgical treatment for lung cancer with pericardial or left atrial invasion]. Kyobu Geka; 2010 May;63(5):360-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of surgical treatment for lung cancer with pericardial or left atrial invasion].
  • We evaluated surgical results for the patients who underwent pulmonary resection combined with pericardial or left atrial resection due to locally advanced non-small cell lung cancer (NSCLC).
  • Seven patients who underwent pericardial resection (T3 group) and 4 patients who underwent resection of the left atrium (T4 group) were included in this study, and clinical findings and prognosis were evaluated.
  • Histology of the cancer was squamous cell carcinoma in all patinets.
  • Induction chemotherapy was performed in 75.0% of T4 group.
  • Extended resection of pericardium or left atrium for patients with N2 disease of NSCLC is not recommended.
  • When invasion to pericardium or left atrium is diagnosed during surgery, extended resection should be indicated in patient without N2 metastasis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Heart Atria / surgery. Lung Neoplasms / surgery. Pericardium / surgery
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Invasiveness. Pneumonectomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446602.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Shitara K, Munakata M, Ishiguro A, Okada R, Tomioka R, Mitobe S, Sakata Y: [A case of recurrent breast cancer complicated with pericardial effusions and cardiac tamponade]. Gan To Kagaku Ryoho; 2006 Jul;33(7):961-4
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent breast cancer complicated with pericardial effusions and cardiac tamponade].
  • A 56-year-old female with breast cancer after left partial mastectomy and subaxillary lymph node dissection was treated with adjuvant chemoradiotherapy.
  • After one year left lung metastasis and malignant pleural effusion had resisted and progressed against several types of chemotherapy.
  • Although combination chemotherapy of trastuzumab and vinorelbine was started, pericardial effusions progressed.
  • Emergent pericardiocentesis was performed, and the catheter was left in the pericardial space.
  • On days 3, 5 and 7, after further pericardial drainage, the intracavitary treatment with a 15 mg bolus of thiotepa and 30 mg hydrocortisone was administered, and the catheter was removed the following day.
  • The recurrence of pericardial effusions was not seen in four months until death.
  • Pericardiocentesis and intrapericardial instillation of thiotepa were effective in our case with pericardial effusions.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Breast Neoplasms / complications. Cardiac Tamponade / etiology. Pericardial Effusion / etiology. Thiotepa / administration & dosage
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Combined Modality Therapy. Cranial Irradiation. Drainage. Female. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local / complications. Neoplasm Recurrence, Local / drug therapy. Quality of Life

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835487.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 905Z5W3GKH / Thiotepa
  •  go-up   go-down


14. Papi M, Genestreti G, Tassinari D, Lorenzini P, Serra S, Ricci M, Pasquini E, Nicolini M, Pasini G, Tamburini E, Fattori PP, Ravaioli A: Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis. Tumori; 2005 May-Jun;91(3):276-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pericardial mesothelioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis.
  • Malignant pericardial mesothelioma is an uncommon variety of a primary malignant cardio-pericardial tumor and it is a highly lethal and fortunately rare cardiac neoplasm.
  • The presentation of pericardial mesothelioma is aspecific and pathologically mesothelioma is not the most common among primary tumors of the pericardium.
  • Antemortem diagnosis is difficult and distant metastases are extremely rare.
  • The treatment for advanced primary pericardial mesothelioma is usually palliative because the tumor is resistant to radiotherapy and chemotherapy.
  • In this paper we report two cases of patients with primary mesothelioma of the pericardium without a definite history of asbestos exposure.
  • [MeSH-major] Heart Neoplasms / pathology. Mesothelioma / pathology. Pericardium / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Humans. Male. Prognosis. Survival

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206657.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


15. Arat M, Ulusoy V, Demirer T, Uysal AV, Ozcan M, Dinçer S, Ilhan O, Koç H: An unusual presentation of plasma cell dyscrasias: cardiac tamponade due to myelomatous infiltration. Leuk Lymphoma; 2002 Jan;43(1):145-8
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of plasma cell dyscrasias: cardiac tamponade due to myelomatous infiltration.
  • Pericardial involvement, a rare complication of multiple myeloma (MM), is caused by amyloidosis, infections, bleeding abnormalities or plasma cell infiltration, usually at a late or terminal stage of the disease.
  • Three cases of MM with pericardial involvement are reported here and discussed in the light of current literature.
  • In a retrospective review of all patients with MM at two institutions, three cases of pericardial involvement were identified.
  • In the remaining two patients, the pericardial biopsy specimen was obtained via a pericardial window.
  • All patients had progressive dyspnea and signs of pericardial tamponade.
  • In the second patient pericardial invasion was proven by biopsy and the third was diagnosed with a plasma cell leukemia but developed a pericardial effusion demonstrated by pericardial biopsy.
  • All these three patients died of progressive disease without any response to chemotherapy and supportive measures.
  • In conclusion, optimal treatment for malignant involvement of the pericardium by myeloma cells has not yet been established and is often fatal.
  • [MeSH-major] Cardiac Tamponade / etiology. Multiple Myeloma / complications
  • [MeSH-minor] Adult. Aged. Female. Heart Neoplasms / complications. Heart Neoplasms / pathology. Humans. Male. Middle Aged. Neoplasm Invasiveness. Paraproteinemias / complications. Paraproteinemias / pathology. Pericardial Effusion / complications. Pericardial Effusion / etiology. Pericarditis / etiology. Pericarditis / pathology

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908719.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


16. Tanoue K, Sanada J, Kayano T, Tanaka H, Terashi T: [Malignant lymphoma with various cardiac manifestations: a case report]. J Cardiol; 2002 Sep;40(3):117-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma with various cardiac manifestations: a case report].
  • A 49-year-old woman presented with malignant lymphoma manifesting as dyspnea, palpitation and leg edema.
  • Chest radiography demonstrated cardiomegaly, electrocardiography(ECG) showed first degree atrioventricular block, and echocardiography showed concentric left ventricular hypertrophy with granular sparkling texture and mild pericardial effusion.
  • The diagnosis was malignant lymphoma(B-cell) based on lymph node biopsy.
  • Chemotherapy(CHOP) was performed under a suspected diagnosis of cardiac invasion of malignant lymphoma.
  • Immediately after chemotherapy, ECG showed complete atrioventricular block with sinus arrest, ventricular fibrillation and atrial fibrillation.
  • ECG was normalized after 2 weeks on chemotherapy.
  • Left ventricular hypertrophy was improved and pericardial effusion disappeared.
  • However, she died of recurrence of malignant lymphoma on day 116.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Administration Schedule. Electrocardiography. Female. Humans. Middle Aged. Neoplasm Invasiveness. Pericardial Effusion / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12325461.001).
  • [ISSN] 0914-5087
  • [Journal-full-title] Journal of cardiology
  • [ISO-abbreviation] J Cardiol
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Maisch B, Ristic A, Pankuweit S: Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis; 2010 Sep-Oct;53(2):157-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation and management of pericardial effusion in patients with neoplastic disease.
  • The incidence and extent of pericardial involvement in neoplastic disease varies.
  • In a considerable number of patients with breast or lung cancer or with mediastinal lymphoma, in addition to direct involvement by the tumor, radiation therapy as well as systemic tumor treatment can also lead to pericardial effusion.
  • In addition, in immunosuppressed tumor patients, pericardial effusion can also arise from viral, bacterial, and autoimmune causes.
  • To distinguish between these 3 different conditions leading to pericardial effusion, the diagnosis should be based on pericardiocentesis followed by fluid analysis for cytology and biomarkers, on epicardial and pericardial biopsy facilitated by flexible pericardioscopy with analysis of specimens by conventional histology and molecular biology techniques for viral and microbial aetiology.
  • We collected prospectively but analyzed retrospectively 357 patients undergoing pericardiocentesis from 1988 to 2008 and identified 68 patients who had cancer-related pericardial effusion.
  • With these methods, 42 patients demonstrated malignant effusion, 15 patients had radiation-induced pericardial, effusion, and in 11 patients without radiation therapy, the effusion could be attributed to either viral infection in 5 cases or to an autoimmune process in the remaining 6 patients.
  • Consequently, intrapericardial treatment could be tailored for each cohort: neoplastic effusion was treated with intrapericardial cisplatin (single instillation of 30 mg/m(2) per 24 hours); in addition to the tumor-specific systemic chemotherapy, intrapericardial triamcinolone acetate (Volon A) was given in a dose of 500 mg/m(2) in the patients with autoimmune and radiation-induced effusion.
  • Saline rinsing and intrapericardial sclerosing treatment were the treatment of choice in viral pericardial effusion.
  • Oral colchicine treatment (2-3 x 0.5 mg) was given in all patients for at least 3 months.
  • Recurrence of pericardial effusion was prevented for at least 3 months in more than 85% of patients.
  • This differential diagnostic approach and the results of treatment were compared with published series.
  • [MeSH-major] Neoplasms / therapy. Pericardial Effusion / diagnosis. Pericardial Effusion / therapy. Radiation Injuries / diagnosis. Radiation Injuries / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Bacterial Infections / complications. Biomarkers / analysis. Biopsy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pericardiocentesis. Polymerase Chain Reaction. Predictive Value of Tests. Radiotherapy / adverse effects. Recurrence. Registries. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Virus Diseases / complications

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20728703.001).
  • [ISSN] 1873-1740
  • [Journal-full-title] Progress in cardiovascular diseases
  • [ISO-abbreviation] Prog Cardiovasc Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers
  •  go-up   go-down


18. Kisselbach C, Ristic AD, Pankuweit S, Karatolius K, Maisch B: [Women and pericardial neoplastic manifestations of the heart and pericardium]. Herz; 2005 Aug;30(5):409-15; quiz 429-30
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Women and pericardial neoplastic manifestations of the heart and pericardium].
  • Despite the proportions, most women believe that heart disease is a man's disease and that they will die of breast cancer.
  • Data on epidemiology and incidence are rare: there is only an estimated incidence of cardiac neoplasm at necropsy ranging from 0,001% to 0,3%.
  • The majority of the primary tumors are benign.
  • The most common tumor entity is benign cardiac myxoma.
  • Malignant heart tumors are less common.
  • Most often they are different types of sarcomas, which have a poor outcome and affect more males than females.
  • Metastatic tumors of the heart are 100 times more common than the primary ones.
  • They originate mainly from melanomas, leukemias, lymphomas, and cancer, especially of the lung or breast.
  • Indeed in women breast cancer is the most common metastatic tumor associated with pericardial effusion.
  • To prevent death from tamponade, pericardiocentesis, in addition to the systemic chemotherapy, is mandatory, best when instillation of chemotherapeutics (cisplatin or thiotepa) or radioisotopes is given into the pericardial sac to prevent recurrence of the effusion.
  • However, more of the malignant tumors may be curable if exactly diagnosed at an earlier stage.
  • METHODS: A retrospective study was conducted of all patients with cardiac and pericardial neoplasm exactly diagnosed by endomyocardial or epicardial biopsy and pericardiocentesis, using hospital medical records and a biopsy and pericardiocentesis registry from 2000-2005 with 297 patients.
  • Pericardial effusion and biopsy analyses included biochemistry, cytology, serology, microbiology, histology, immunohistology, and polymerase chain reaction (PCR).
  • RESULTS: In 76 cases (25.6%) a neoplasm was the reason for a pericardial effusion.
  • 36 women suffered from the breast carcinoma (47%) and 40 males lung cancer (42%) as the firstly metastatic tumor.
  • There was no recurrence of a relevant pericardial effusion in patients who were treated by intrapericardial instillation of cisplatin (30 mg/m2 body surface in 100 ml 0.9% NaCl).
  • CONCLUSION: Females are more often affected by primary cardiac tumors than males with an excellent outcome.
  • By contrast, the preventive checkup and aftercare will gain more prognostic importance, especially in case of breast cancer, to earlier recognize a secondary cardiac neoplasm by biopsy and pericardiocentesis with intrapericardial treatment of neoplastic pericarditis.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132244.001).
  • [ISSN] 0340-9937
  • [Journal-full-title] Herz
  • [ISO-abbreviation] Herz
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


19. Tomkowski WZ, Wiśniewska J, Szturmowicz M, Kuca P, Burakowski J, Kober J, Fijałkowska A: Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer; 2004 Jan;12(1):53-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade.
  • GOALS: To evaluate the effectiveness and side effects of intrapericardial administration of cisplatin in prevention of recurrent malignant pericardial effusion.
  • The diagnosis of malignancy was based upon histological examination of samples from primary tumor.
  • The majority of patients suffered from a neoplasm localized in the thorax (41 out of 46 patients; 89%).
  • In 35 cases, pericardiocentesis, and in 11 cases, video-assisted thoracoscopic surgery (VATS) of pericardium was performed.
  • Malignant etiology of pericardial fluid was confirmed by cytological examination, histology being obtained by VATS pericardial biopsy or by echocardiography (ECG).
  • If daily drainage of pericardial fluid observed during 5-7 days exceeded 50 ml, cisplatin was instilled according to one of three regimens:.
  • (1) 10 mg of cisplatin dissolved in 20 ml of normal saline administered over 5 min during 5 consecutive days directly into the pericardial space (39 patients);.
  • Treatment was considered as successful when recurrence of symptoms of large pericardial effusion was not observed in ECG and other interventions directed to the pericardium were not required.
  • Efficacy of investigated treatment was assessed also in the group of patients with survival longer than 30 days.
  • Safety of treatment was assessed in the whole group of patients.
  • Positive effect of intrapericardial treatment with cisplatin was achieved in 43 out of 46 patients (93.5%) in the entire investigated group and in 35 out of 38 patients (92%) who survived more than 30 days.
  • In the subgroup of patients with non-small cell lung cancer (NSCLC) and survival longer than 30 days, high efficacy was documented (29 out of 31 cases; 93.5%).
  • Median survival time in the group of 38 patients who survived more than 30 days was 102.5 days.
  • Sclerosis of the pericardial space without symptoms of constriction occurred in five out of 46 cases (10.9%).
  • CONCLUSIONS: Cisplatin administered directly into the pericardial space is a very effective and relatively safe method of treatment of recurrent malignant pericardial effusion, especially in the course of NSCLC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cardiac Tamponade / etiology. Cisplatin / administration & dosage. Lung Neoplasms / surgery. Pericardial Effusion / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Small Cell / surgery. Drainage. Female. Humans. Injections, Intralesional. Male. Middle Aged. Pericardiocentesis / adverse effects. Pericardium. Recurrence. Survival Analysis. Thoracic Surgery, Video-Assisted / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 1997 Mar;16(2-3):215-22 [9152952.001]
  • [Cites] JAMA. 1994 Jul 6;272(1):59-64 [8007081.001]
  • [Cites] Chest. 1999 Aug;116(2):275-6 [10453849.001]
  • [Cites] Monaldi Arch Chest Dis. 1995 Apr;50(2):86-8 [7613552.001]
  • [Cites] Oncology. 1994 Nov-Dec;51(6):507-9 [7526307.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3141-7 [8955660.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):437-42 [1617593.001]
  • [Cites] Am J Med. 1998 Aug;105(2):106-9 [9727816.001]
  • [Cites] Mayo Clin Proc. 1998 Jul;73(7):647-52 [9663193.001]
  • [Cites] Cancer. 1990 Mar 15;65(6):1456-9 [2306690.001]
  • [Cites] Chest. 1996 Jun;109(6):1452-4 [8769492.001]
  • [Cites] Herz. 2000 Dec;25(8):787-93 [11200128.001]
  • [Cites] Support Care Cancer. 1997 Jan;5(1):64-6 [9010992.001]
  • [Cites] Ann Thorac Surg. 1997 Nov;64(5):1422-7; discussion 1427-8 [9386714.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2371-6 [9667253.001]
  • [Cites] Chest. 1998 Apr;113(4):861-6 [9554616.001]
  • [Cites] Mayo Clin Proc. 2000 Mar;75(3):248-53 [10725950.001]
  • [Cites] Monaldi Arch Chest Dis. 1997 Jun;52(3):221-4 [9270245.001]
  • [Cites] Am J Cardiol. 1987 Nov 15;60(14):1161-6 [2446487.001]
  • [Cites] Circulation. 1962 Aug;26:228-41 [14037856.001]
  • [Cites] J Cardiothorac Vasc Anesth. 1993 Apr;7(2):178-83 [8477023.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Sep;112(3):637-43 [8800150.001]
  • [Cites] JAMA. 1987 Feb 27;257(8):1088-92 [3806903.001]
  • [Cites] Chest. 1997 Oct;112(4 Suppl):291S-295S [9337306.001]
  • [Cites] Eur Heart J. 2002 Oct;23(20):1625-31 [12323163.001]
  • (PMID = 14505155.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Hasegawa S, Tanaka F: Malignant mesothelioma: current status and perspective in Japan and the world. Gen Thorac Cardiovasc Surg; 2008 Jul;56(7):317-23
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma: current status and perspective in Japan and the world.
  • Malignant pleural mesothelioma (MPM) is associated with a poor prognosis; and to make things worse, its incidence is increasing throughout the world.
  • Surgical management of MPM is comprised of two aspects: diagnosis and resection.
  • Surgical biopsy with thoracoscopy provides a higher yield but a higher rate of tumor cell seeding than blind biopsy.
  • There are two types of surgical resection for MPM.
  • Pleurectomy/decortication (P/D) involves removal of as much of the visceral, parietal, and pericardial pleura and the tumor as possible without removing the underlying lung.
  • EPP comprises en bloc resection of visceral, parietal, and pericardial pleura and adjacent components such as ipsilateral lung, pericardium, and diaphragm, without opening the pleural cavity.
  • EPP was considered a highly dangerous procedure with a surgical mortality of more than 30% decades ago, but its current operative mortality/morbidity rates are 4%-9% and 60%, respectively.
  • As macroscopic complete resection is the primary goal of surgery for MPM because of its diffuse intrapleural growth, surgical resection alone is associated with poor survival.
  • In this context, combination therapy with surgery plus chemotherapy and/or radiotherapy is currently considered the standard treatment for patients with respectable MPM.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy. Thoracic Surgical Procedures
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Humans. Japan. Laparoscopy. Mediastinoscopy. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant. Thoracoscopy. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cardiothorac Surg. 1999 Dec;16(6):619-23 [10647830.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2629-30 [12860935.001]
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):1039-47 [10587144.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jul;128(1):138-46 [15224033.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Oncologist. 2007 Jul;12(7):850-63 [17673616.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 May;131(5):981-7 [16678579.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 May;31(5):765-70; discussion 770-1 [17337201.001]
  • [Cites] Ann Thorac Surg. 2005 Dec;80(6):1988-92; discussion 1992-3 [16305830.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Radiology. 2006 Nov;241(2):589-94 [17005770.001]
  • [Cites] Eur J Radiol. 2007 Dec;64(3):356-66 [17954021.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):389-93 [8319170.001]
  • [Cites] Interact Cardiovasc Thorac Surg. 2008 Feb;7(1):102-6 [18048410.001]
  • [Cites] Chest. 2003 Feb;123(2):551-61 [12576380.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1183-5 [15451229.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):175-6 [17409850.001]
  • [Cites] Br J Cancer. 1998 Mar;77(6):907-12 [9528833.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1172-8 [8501504.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S27-32 [15950796.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):489-94 [8876892.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S25-6 [15950795.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):25-30 [10458214.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Sep;130(3):905-6 [16153957.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S71-4 [15950805.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):342-5 [11875695.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Apr;29(4):579-84 [16495068.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1774-6 [15511473.001]
  • [Cites] J Thorac Imaging. 2006 May;21(2):146-53 [16770231.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1224-30 [11571736.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] Am J Ind Med. 2006 Jan;49(1):1-7 [16362942.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1249-53 [17066226.001]
  • [Cites] Ann Thorac Surg. 2006 Dec;82(6):2337; author reply 2337-8 [17126172.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):57-65 [11162867.001]
  • [Cites] Kyobu Geka. 2007 Jan;60(1):19-24 [17249533.001]
  • [Cites] Ann Thorac Surg. 2007 Nov;84(5):1685-92; discussion 1692-3 [17954086.001]
  • [Cites] J Nucl Med. 2007 Sep;48(9):1449-58 [17704250.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3451-7 [15337794.001]
  • [Cites] J Thorac Oncol. 2007 Oct;2(10):957-65 [17909360.001]
  • [Cites] Lung Cancer. 2001 Nov;34(2):279-87 [11679187.001]
  • [Cites] AJR Am J Roentgenol. 1990 Mar;154(3):487-92 [2106209.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jan;29(1):14-9 [16343925.001]
  • [Cites] Thorax. 2007 Nov;62 Suppl 2:ii1-ii19 [17965072.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Jun;133(6):1414-8 [17532931.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):367-72 [9352954.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Feb;11(2):210-3 [9080144.001]
  • [Cites] Lung Cancer. 2007 Aug;57 Suppl 2:S24-9 [17686442.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5 [16751058.001]
  • (PMID = 18607677.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 60
  •  go-up   go-down


21. Scripcariu V, Dajbog E, Lefter L, Ferariu D, Pricop A, Grigoraş M, Dragomir C: [Malignant peritoneal mesothelioma]. Chirurgia (Bucur); 2006 Nov-Dec;101(6):641-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma].
  • [Transliterated title] Mezoteliomul malign peritoneal.
  • Mesothelioma is a neoplasm originating from the mesothelial surface lining cells of the serous human cavities.
  • It may involve the pleura, less frequently the peritoneum rarely, the pericardium, the tunica vaginalis testis and ovarian epithelium.
  • A causal relationship between asbestos exposure and pleural, peritoneal and pericardial malign mesothelioma was suggested, the risk of cancer being correlated to cumulate exposure.
  • Studies from National Cancer Institute, USA, show that the malignant mesothelioma is a rare and aggressive asbestos related malignancy.
  • The symptomatology is insidious and poses difficult problems in diagnosis and treatment.
  • This paper presents the case of a 59 year old patient with malignant peritoneal mesothelioma who worked almost 40 years as an electrician, exposed to asbestos fibers.
  • He was hospitalized for important weight loss, abdominal pain and tiredness being diagnosed after imaging tests with a giant tumor, localized at the abdominal upper level, which seems to originate from the spleen's superior pole.
  • During surgery we discovered a tumor with cystic parts, intense vascularized, which turn to be adherent in the upper side to the lower face of the left midriff cupola, to the spleen superior pole and 1/3 middle level of the great gastric curve.
  • It was performed surgical ablation of the tumor, splenectomy with favorable postoperative evolution, the patient being now under chemotherapy treatment.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Middle Aged. Splenectomy. Tomography, X-Ray Computed. Treatment Outcome


22. Minagawa T, Murata Y, Uchikawa S, Uehara T: Malignant pericardial tamponade in a patient with hormone-refractory prostate cancer. Int J Clin Oncol; 2010 Feb;15(1):101-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial tamponade in a patient with hormone-refractory prostate cancer.
  • An 82-year-old man who was receiving treatment for prostate cancer and cholangiocellular carcinoma was admitted to our hospital because of chest discomfort and dyspnea.
  • At the time of admission, 16 months after the start of hormone therapy, the prostate-specific antigen level was 454.08 ng/ml.
  • Chest radiography revealed cardiomegaly, and ultrasonography demonstrated significant pericardial effusion.
  • Pericardiocentesis yielded a hemorrhagic exudate, and a routine cytological study revealed malignant cells.
  • It was difficult to determine whether these cells had originated from the prostate cancer or the cholangiocellular carcinoma.
  • However, immunohistochemical analysis of a cell-block section of the pericardial effusion allowed a diagnosis of pericardial metastasis from the prostate cancer.
  • After removal of the pericardial drain, the patient was discharged, but the pericardial effusion was found to have accumulated again 1 month later.
  • [MeSH-major] Cardiac Tamponade / etiology. Heart Neoplasms / secondary. Pericardium. Prostatic Neoplasms / complications
  • [MeSH-minor] Aged, 80 and over. Bile Duct Neoplasms / complications. Cholangiocarcinoma / complications. Cisplatin / therapeutic use. Diterpenes, Abietane / therapeutic use. Drug Resistance, Neoplasm. Humans. Male. Pericardial Effusion / drug therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Isr J Med Sci. 1988 Aug;24(8):417-9 [3410672.001]
  • [Cites] Cancer Treat Rep. 1977 Nov;61(8):1607 [922763.001]
  • [Cites] Pol Tyg Lek. 1992 Jun 15-29;47(24-26):552-3 [1480528.001]
  • [Cites] Wiad Lek. 1993 Aug;46(15-16):615-8 [7975589.001]
  • [Cites] Heart. 1996 Jan;75(1):67-71 [8624876.001]
  • [Cites] Urology. 2002 Jan;59(1):137 [11796304.001]
  • [Cites] Urology. 1975 Feb;5(2):233-5 [1114562.001]
  • [Cites] Cancer. 1954 Nov;7(6):1246-8 [13209524.001]
  • [Cites] Cancer. 1972 Mar;29(3):799-808 [4501215.001]
  • [Cites] South Med J. 1967 Jul;60(7):781-2 [6029331.001]
  • [Cites] Hinyokika Kiyo. 2008 May;54(5):369-72 [18546864.001]
  • [Cites] Am J Clin Pathol. 1991 Jun;95(6):867-74 [1710419.001]
  • [Cites] Med Clin (Barc). 1995 Mar 25;104(11):436 [7715265.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1377-87 [8620412.001]
  • (PMID = 20066456.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Diterpenes, Abietane; OR166S9YJA / horminone; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Hammerschmidt S, Pohlink C, Wirtz H, Rother T: [Alternating electric heart axis in a patient with small cell lung cancer]. Dtsch Med Wochenschr; 2004 Jan 2;129(1-2):19-22
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alternating electric heart axis in a patient with small cell lung cancer].
  • [Transliterated title] Alternierende elektrische Herzachse bei einem Patienten mit kleinzelligem Lungenkarzinom.
  • HISTORY AND ADMISSION FINDINGS: A 62-year-old man was admitted because of recurrent abdominal pain 18 months after small cell lung cancer (SCLC) had been diagnosed and remission achieved with chemotherapy and radiotherapy.
  • Symptomatic treatment brought improvement, but 16 hours after admission the patient complained of severe diffuse abdominal pain.
  • Chest radiogram demonstrated a double-contour cardiac silhouette suggesting a large pericardial effusion, confirmed on echocardiography, which also showed a pendulum-like cardiac motion.
  • The needle aspirate of the pericardial fluid contained malignant cells.
  • DIAGNOSIS: These findings indicated malignant, hemodynamically significant pericardial effusion due to a recurrence of SCLC, with pronounced abdominal symptoms and advanced right heart failure.
  • TREATMENT AND COURSE: Pericardiocentesis brought about marked improvement.
  • 30 mg cisplatin was injected into the pericardial sac and chemotherapy resumed.
  • There was no tumor progression over the following 4 months when the pericardial effusion recurred, chemotherapy (4 cycles of carboplatin and etoposide) was restarted and another infusion of cisplatin undertaken.
  • CONCLUSION: This case report illustrates a not uncommon manifestation of lung cancer, malignant pericardial effusion, first becoming symptomatic as severe abdominal pain.
  • Characteristic changes in the chest radiogram and the ECG provided the diagnosis, confirmed histologically.
  • [MeSH-major] Carcinoma, Small Cell / complications. Heart Conduction System / physiopathology. Lung Neoplasms / complications. Neoplasm Recurrence, Local / complications. Pericardial Effusion / diagnosis
  • [MeSH-minor] Abdominal Pain / etiology. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Echocardiography. Electrocardiography. Etoposide / therapeutic use. Humans. Male. Middle Aged. Pericardiocentesis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14703576.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


24. Takahashi T, Sakamoto J, Kosaka S: [Metastatic lung tumor from uterine leiomyosarcoma; report of a case]. Kyobu Geka; 2008 Jul;61(7):595-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic lung tumor from uterine leiomyosarcoma; report of a case].
  • Endometrial leimyosarcoma is rare neoplasm of all the uterine malignancies.
  • We herein present a case of metastatic pulmonary tumor derived from endometrial leiomyosarcoma She had undergone hysterectomy for leiomyosarcoma.
  • Following chemotherapy of cisplatin, ifomide and pirarubicine, right hepatectomy was performed.
  • The mass grew so rapidly with involvement to adjacent organs that pericardial resection was necessary with completion right lower lobectomy.
  • Postoperative chemotherapy was performed with the same regimen as previously performed.
  • About 10 months after the second pulmonary resection, she died due to dissemination in the right haemithorax and malignant pericardial effusion.
  • Careful follow up after the surgery for the uterine leiomyosarcoma is recommended because metastatic leiomyosarcoma possibly appears even after a long interval, and its progress can be so intensive that adjuvant chemotherapy is necessary if it can not be treated surgically alone.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616110.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Funk L, Hartmann D, Apel D, Spiethoff A, Schiele R, Schilling D, Adamek HE, Riemann JF: [Symptomatic pericardial effusion as initial manifestation of gastric signet ring cell carcinoma]. Dtsch Med Wochenschr; 2003 Apr 17;128(16):870-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Symptomatic pericardial effusion as initial manifestation of gastric signet ring cell carcinoma].
  • The health history included the diagnosis of diabetes mellitus and chronic obstructive pulmonary disease.
  • The echocardiography revealed pericardial effusion.
  • Endoscopic study revealed a 3 cm tumor in the posterior wall of the upper part of the body.
  • The histopathological examination diagnosed cancer of diffuse type according to Lauren, with signet-ring cells.
  • TREATMENT AND CLINICAL COURSE: After treating the atrial fibrillation a pericardial drainage was performed.
  • In an echocardiogram after pericardial drainage, pericardial effusion was no longer present.
  • During the clinical course the patient suffered a stroke and the chemotherapy could not be initiated.
  • The patient died 2 months after diagnosis.
  • CONCLUSION: Cardiac involvement with clinical manifestations and pericardial effusion may be associated with a malignant neoplasm.
  • Echocardiography and pericardiocentesis are helpful for the diagnosis of cardiac metastases.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Pericardial Effusion / etiology. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged. Atrial Fibrillation / diagnosis. Atrial Fibrillation / etiology. Atrial Fibrillation / therapy. Drainage. Dyspnea. Fatal Outcome. Female. Gastroscopy. Humans. Pericardiocentesis. Tachycardia

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701032.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement